Vinit Nijhawan
Managing Director at MassVentures
Cambridge, Massachusetts
Overview
Work Experience
Managing Director
2020 - Current
MTTC merged into MassVentures. MassVentures, a quasi-public entity was founded in 1978 and is focused on Deep Tech non-dilutive and dilutive funding with an added focus on diverse founders.
Interim Executive Director MTTC
2018 - 2020
MTTC enables Massachusetts public and private research universities and medical centers to lead the nation in translating basic research to the market, creating jobs and economic development to benefit Americans. Merged with MassVentures.
MassVentures is a venture capital firm focused on supporting Massachusetts-based startups to prosper in their businesses.
Raised $1,000,000.00 from US Department of Commerce, Economic Development Administation.
Board Member
2023
Suturing tools for endoscopes
EnVision Endoscopy is a medical device that provides endoscopic surgeries with solutions.
Raised $3,368,452.00 from MassVentures, MassVentures, MassVentures, National Science Foundation, National Science Foundation, MassChallenge, Massachusetts Life Sciences Center and National Science Foundation.
MBA Lecturer
2008
As a Lecturer teach MBA, Engineering and Medicine courses on entrepreneurship, and member of the Faculty Innovation Network of the BuildLab. Have taught entrepreneurship to over 600 students.
Managing Director Office of Technology Development
2010 - 2016
Launched eight venture-backed spinoffs (who have cumulatively raised over $350M) and generated more licensing royalty income than 34 years cumulative prior. Member of Coulter Oversight Committee at Biomedical Engineering. Member of BU CTSI Internal Advisory Board. Member of the Fraunhofer Alliance. Past member of the Conflict of Interest Committees for BU and BU School of Medicine.
Investor and Board Observer
2023
Investor and Board Advisor
2022
InGel Therapeutics is a platform technology company that develops stem cell therapeutics and biodegradable polymers.
Investor and Board Observer
2022
Investor and Board Observer
2022
Adden Energy is a developer of stable, lithium-metal, solid-state batteries.
Raised $20,149,974.00 from At One Ventures, MassVentures, Primavera Capital Group and Rhapsody Venture Partners.
Investor and Board Observer
2022
Investor and Board Observer
2021
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Raised $39,098,461.00 from National Institute of Allergy and Infectious Diseases.
Investor and Board Observer
2020
Concerto Biosciences reinvents humanity's relationship with microbes.
Raised $26,006,949.00 from Springboard Enterprises.